Journal of Gastroenterology

, Volume 42, Supplement 17, pp 41–47 | Cite as

Role of infection in irritable bowel syndrome

  • Robin C. Spiller
Article

Abstract

Infection by pathogenic organisms leads to mucosal damage and disruption of the gut's extensive commensal flora, factors which may lead to prolonged bowel dysfunction. Six to 17% of unselected irritable bowel syndrome (IBS) patients believe their symptoms began with an infection, which is supported by prospective studies showing a 4%–31% incidence of postinfectious IBS-(PI) sfollowing bacterial gastroenteritis. The wide range of incidence can be accounted for by differences in risk factors, which include in order of magnitude; severity of initial illness > bacterial toxigenicity > hypochondriasis, depression and neuroticism, and adverse life events in the previous 3 months. PI-IBS has been reported after Campylobacter, Salmonella, and Shigella infections. Serial biopsies after Campylobacter jejuni gastroenteritis show an initial inflammatory infiltrate, with an increase in enterochromaffin (EC) cells, which in most cases subsides over the next 6 months. Those who go on to develop IBS show increased numbers of EC and lymphocyte cell counts at 3 months compared with those who do not develop IBS. Interleukin-1β mRNA levels are increased in the mucosa of those who develop PI-IBS, who also show increased gut permeability. Recover can be slow, with approximately 50% still having symptoms at 5 years. Recent studies suggest an increase in peripheral blood mononuclear cell cytokine production in unselected IBS, an abnormality that may be ameliorated by probiotic treatment. The role of small-bowel bacterial overgrowth in IBS is controversial, but broad-spectrum antibiotics do have a temporary benefit in some patients. More acceptable long-term treatments altering gut flora are awaited with interest.

Key words

irritable bowel syndrome infection inflammation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Spiller, RC, Jenkins, D, Thornley, JP, Hebden, JM, Wright, T, Skinner, M,  et al. 2000Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndromeGut4780411PubMedCrossRefGoogle Scholar
  2. 2.
    Sanovic, S, Lamb, DP, Blennerhassett, MG 1999Damage to the enteric nervous system in experimental colitisAm J Pathol15510517PubMedGoogle Scholar
  3. 3.
    Neal, KR, Hebden, J, Spiller, R 1997Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patientsBr Med J31477982Google Scholar
  4. 4.
    Thompson, WG, Longstreth, GF, Drossman, DA, Heaton, KW, Irvine, EJ, Muller-Lissner, SA 1999Functional bowel disorders and functional abdominal painGut45II437PubMedCrossRefGoogle Scholar
  5. 5.
    Dunlop, SP, Jenkins, D, Neal, KR, Spiller, RC 2003Clinical and histological features of post-infectious IBS: relative importance of enterochromaffin cell hyperplasia, anxiety and depressionGastroenterology12516519PubMedCrossRefGoogle Scholar
  6. 6.
    Dunlop, SP, Jenkins, D, Spiller, RC 2003Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndromeAm J Gastroenterol98157883PubMedCrossRefGoogle Scholar
  7. 7.
    Wang, LH, Fang, XC, Pan, GZ 2004Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesisGut531096101PubMedCrossRefGoogle Scholar
  8. 8.
    Thornley, JP, Jenkins, D, Neal, K, Wright, T, Brough, J, Spiller, RC 2001Relationship of Campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndromeJ Infect Dis1846069PubMedCrossRefGoogle Scholar
  9. 9.
    Dunlop, SP, Jenkins, D, Neal, KR, Spiller, RC 2003Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBSGastroenterology12516519PubMedCrossRefGoogle Scholar
  10. 10.
    Wheatcroft, J, Wakelin, D, Smith, A, Mahoney, CR, Mawe, G, Spiller, R 2005Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunctionNeurogastroenterol Motil1786370PubMedCrossRefGoogle Scholar
  11. 11.
    Gwee, KA, Leong, YL, Graham, C, McKendrick, MW, Collins, SM, Walters, SJ,  et al. 1999The role of psychological and biological factors in postinfective gut dysfunctionGut444006PubMedCrossRefGoogle Scholar
  12. 12.
    Dunlop, SP, Jenkins, D, Spiller, RC 2004Age-related decline in rectal mucosal lymphocytes and mast cellsEur J Gastroenterol Hepatol1610115PubMedCrossRefGoogle Scholar
  13. 13.
    Zigmond, AS, Snaith, RP 1983The hospital anxiety and depression scaleActa Psychiatr Scand6736170PubMedGoogle Scholar
  14. 14.
    Gwee, KA, Graham, JC, McKendrick, MW, Collins, SM, Marshall, JS, Walters, SJ,  et al. 1996Psychometric scores and persistence of irritable bowel after infectious diarrhoeaLancet3471503PubMedCrossRefGoogle Scholar
  15. 15.
    Kidd, M, Modlin, IM, Eick, GN, Champaneria, MC 2006Isolation, functional characterization and transcriptome of mastomys ileal enterochromaffin cellsAm J Physiol Gastrointest Liver Physiol291G77891PubMedCrossRefGoogle Scholar
  16. 16.
    Atkinson, W, Lockhart, S, Whorwell, PJ, Keevil, B, Houghton, LA 2006Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndromeGastroenterology1303443PubMedCrossRefGoogle Scholar
  17. 17.
    Dunlop, SP, Coleman, NS, Blackshaw, E, Perkins, AC, Singh, G, Marsden, CA,  et al. 2005Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndromeClin Gastroenterol Hepatol334957PubMedCrossRefGoogle Scholar
  18. 18.
    Coates, MD, Mahoney, CR, Linden, DR, Sampson, JE, Chen, J, Blaszyk, H,  et al. 2004Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndromeGastroenterology126165764PubMedCrossRefGoogle Scholar
  19. 19.
    Andrews, C, Camilleri, M, Bharucha, AE, Carlson, PJ, Ferber, I, Stephens, D,  et al. 2006Serotonin-transporter (SERT) polymorphism genotype and SERT expression in mucosal biopsies of patients with irritable bowel syndromeGastroenterology125A61Google Scholar
  20. 20.
    Caspi, A, Sugden, K, Moffitt, TE, Taylor, A, Craig, IW, Harrington, H,  et al. 2003Influence of life stress on depression: moderation by a polymorphism in the 5-HTT geneScience3013869PubMedCrossRefGoogle Scholar
  21. 21.
    Lee, HJ, Lee, MS, Kang, RH, Kim, H, Kim, SD, Kee, BS,  et al. 2005Influence of the serotonin transporter promoter gene polymorphism on susceptibility to posttraumatic stress disorderDepress Anxiety211359PubMedCrossRefGoogle Scholar
  22. 22.
    Yeo, A, Boyd, P, Lumsden, S, Saunders, T, Handley, A, Stubbins, M,  et al. 2004Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in womenGut5314528PubMedCrossRefGoogle Scholar
  23. 23.
    Linden, DR, White, SL, Foley, K, Stirling, LD, Mawe, GM 2005Evidence for a distinct mechanism of serotonin transporter gene regulation in the human intestine involving a novel splice variantGastroenterology128A59Google Scholar
  24. 24.
    Chadwick, VS, Chen, W, Shu, D, Paulus, B, Bethwaite, P, Tie, A,  et al. 2002Activation of the mucosal immune system in irritable bowel syndromeGastroenterology122177883PubMedCrossRefGoogle Scholar
  25. 25.
    Barbara, G, Stanghellini, V, De Giorgio, R, Cremon, C, Cottrell, GS, Santini, D,  et al. 2004Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndromeGastroenterology126693702PubMedCrossRefGoogle Scholar
  26. 26.
    Gwee, KA, Collins, SM, Read, NW, Rajnakova, A, Deng, Y, Graham, JC,  et al. 2003Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndromeGut525236PubMedCrossRefGoogle Scholar
  27. 27.
    Galeazzi, F, Haapala, EM, van Rooijen, N, Vallance, BA, Collins, SM 2000Inflammation-induced impairment of enteric nerve function in nematode-infected mice is macrophage dependentAm J Physiol Gastrointest Liver Physiol278G25965PubMedGoogle Scholar
  28. 28.
    Xia, Y, Hu, HZ, Liu, S, Ren, J, Zafirov, DH, Wood, JD 1999IL-1beta and IL-6 excite neurons and suppress nicotinic and noradrenergic neurotransmission in guinea pig enteric nervous systemJ Clin Invest103130916PubMedCrossRefGoogle Scholar
  29. 29.
    Dunlop, SP, Hebden, JM, Naesdal, J, Olbe, L, Perkins, AC, Spiller, RC 2006Abnormal intestinal permeability in subgroups of diarrhoea predominant irritable bowel syndromesAm J Gastroenterol101128894PubMedCrossRefGoogle Scholar
  30. 30.
    Marshall, JK, Thabane, M, Garg, AX, Clark, W, Meddings, J, Collins, SM 2004Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, OntarioAliment Pharmacol Ther20131722PubMedCrossRefGoogle Scholar
  31. 31.
    Campbell, E, Richards, M, Foley, S, Hastings, M, Whorwell, P, Mahida, Y,  et al. 2006Markers of inflammation in IBS: increased permeability and cytokine production in diarrhoea-predominant subgroupsGastroenterology130A51CrossRefGoogle Scholar
  32. 32.
    O'Mahony, L, McCarthy, J, Kelly, P, Hurley, G, Luo, F, Chen, K,  et al. 2005Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profilesGastroenterology12854151PubMedCrossRefGoogle Scholar
  33. 33.
    Holtmann, G, Talley, NJ, Liebregts, T, Adam, B, Parow, C 2006A placebo-controlled trial of itopride in functional dyspepsiaN Engl J Med35483240PubMedCrossRefGoogle Scholar
  34. 34.
    Dinan, TG, Quigley, EM, Ahmed, SM, Scully, P, O'brien, S, O'Mahony, L,  et al. 2006Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?Gastroenterology13030411PubMedCrossRefGoogle Scholar
  35. 35.
    Maes, M, Song, C, Lin, A, De Jongh, R, Van Gastel, A, Kenis, G,  et al. 1998The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxietyCytokine103138PubMedCrossRefGoogle Scholar
  36. 36.
    Chang, L 2004Review article: epidemiology and quality of life in functional gastrointestinal disordersAliment Pharmacol Ther20319PubMedCrossRefGoogle Scholar
  37. 37.
    Linden, DR, Chen, JX, Gershon, MD, Sharkey, KA, Mawe, GM 2003Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitisAm J Physiol Gastrointest Liver Physiol285G20716PubMedGoogle Scholar
  38. 38.
    Cremonini, F, Delgado-Aros, S, Camilleri, M 2003Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trialsNeurogastroenterol Motil157986PubMedCrossRefGoogle Scholar
  39. 39.
    Christofi, FL, Kim, M, Wunderlich, JE, Xue, J, Suntres, Z, Cardounel, A,  et al. 2004Endogenous adenosine differentially modulates 5-hydroxytryptamine release from a human enterochromaffin cell modelGastroenterology127188202PubMedCrossRefGoogle Scholar
  40. 40.
    Pimentel, M, Chow, EJ, Lin, HC 2003Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled studyAm J Gastroenterol984129PubMedGoogle Scholar
  41. 41.
    Riordan, SM, McIver, CJ, Walker, BM, Duncombe, VM, Bolin, TD, Thomas, MC 1996The lactulose breath hydrogen test and small intestinal bacterial overgrowthAm J Gastroenterol911795803PubMedGoogle Scholar
  42. 42.
    Anand, AC, Reddy, PS, Saiprasad, GS, Kher, SK 1997Does non-dysenteric intestinal amoebiasis exist?Lancet3498992PubMedCrossRefGoogle Scholar
  43. 43.
    King, TS, Elia, M, Hunter, JO 1998Abnormal colonic fermentation in irritable bowel syndromeLancet35211879PubMedCrossRefGoogle Scholar
  44. 44.
    Maxwell, PR, Rink, E, Kumar, D, Mendall, MA 2002Antibiotics increase functional abdominal symptomsAm J Gastroenterol971048PubMedCrossRefGoogle Scholar
  45. 45.
    Sheil, B, McCarthy, J, O'Mahony, L, Bennett, MW, Ryan, P, Fitzgibbon, JJ,  et al. 2004Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritisGut53694700PubMedCrossRefGoogle Scholar
  46. 46.
    Verdu, EF, Collins, SM 2005Irritable bowel syndrome and probiotics: from rationale to clinical useCurr Opin Gastroenterol21697701PubMedCrossRefGoogle Scholar
  47. 47.
    Penner, R, Fedorak, RN, Madsen, KL 2005Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseasesCurr Opin Pharmacol5596603PubMedCrossRefGoogle Scholar
  48. 48.
    Whorwell, PJ, Altringer, L, Morel, J, Bond, Y, O'Mahony, L, Kiely, B,  et al. 2005Benefits associated with supplementation with an encapsulated probiotic preparation in subjects with irritable bowel syndromeGastroenterology128A469Google Scholar
  49. 49.
    Weston, AP, Biddle, WL, Bhatia, PS, Miner, PB,Jr 1993Terminal ileal mucosal mast cells in irritable bowel syndromeDig Dis Sci3815905PubMedCrossRefGoogle Scholar
  50. 50.
    O'Sullivan, M, Clayton, N, Breslin, NP, Harman, I, Bountra, C, McLaren, A,  et al. 2000Increased mast cells in the irritable bowel syndromeNeurogastroenterol Motil1244957PubMedCrossRefGoogle Scholar
  51. 51.
    Park, JH, Rhee, PL, Kim, G, Lee, JH, Kim, YH, Kim, JJ,  et al. 2006Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndromeNeurogastroenterol Motil1853946PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 2007

Authors and Affiliations

  • Robin C. Spiller
    • 1
  1. 1.Wolfson Digestive Diseases CentreUniversity HospitalNottinghamUK

Personalised recommendations